The INK4a gene on chromosome 9p21 is one of the most common targets for inactivation in human neoplasia. The gene is unusual in that it encodes two structurally unrelated proteins, p16
INK4a and p14 ARF , the human homologue of murine p19 ARF . Two different first exons are spliced in different reading frames to common exon 2 (1). p16
INK4a acts as a retinoblastoma protein (pRB) agonist by inhibiting the phosphorylation of pRB by activated cyclin-dependent kinases 4 and 6 (2) . The principal methods of p16
INK4a inactivation are homozygous deletion of the gene, promoter methylation of exon 1␣, and intragenic mutation (3) . The frequency of p16
INK4a inactivation in human neoplasia rivals that of p53. We previously demonstrated that immunohistochemistry (IHC) is a sensitive and specific method of detecting the absence of functional p16
INK4a in formalin-fixed, paraffin-embedded tumors, whatever the underlying mechanism (4, 5) . In contrast, p14 ARF primarily acts as a p53 agonist by inhibiting the MDM2-mediated degradation of the latter (6, 7) . p14 ARF can also be inactivated by homozygous deletion, promoter hypermethylation, and, presumably, intragenic mutation, although no mutations selectively targeting exon 1␤ have been described (1) . Promoter methylation of exons 1␣ and 1␤ appear to be independent events (8) , and comparatively few data exist on the frequency of p14 ARF inactivation in human neoplasia. An important reason for this relative lack of data may be the unavailability of an assay that would allow the evaluation of p14 ARF expression in archival tissues. Here we describe such an assay, which utilizes commercially available reagents and which should be ap-plicable in any immunohistochemical laboratory. We demonstrate the validity of our method and its application to paraffin-embedded cell lines and tumors, and we provide evidence that, at least in some human cancers, p14 ARF abrogation, although important, may be less common than, and independent of, p16
INK4a inactivation.
MATERIALS AND METHODS

Cell Lines and Tissues
All lung cancer and mesothelioma cell lines (designated by the prefix "H") were originally established at the National Cancer Institute-Navy Medical Oncology Branch (9) . Breast cancer cell lines MCF-10A, SKBR3, BT474, T47D, MDA-MB-231, MDA-MB-361, and MDA-MB-468 were provided by the Imperial Cancer Research Fund Clare Hall Laboratories (London, UK). Colorectal carcinoma cell lines SW480, SW620, SW837, SW1463, RKO and DLD-1, and cell lines PC-3 and U2OS, as well as a nude mouse xenografts of cell lines H417 and H2009, had been used in previous immunohistochemical studies (4, 10, 11) . The non-small cell lung cancers (NSCLC) were part of a cohort of wellcharacterized tumors from Australia (12) . The pancreatic carcinomas were from the pathology files of the Johns Hopkins Medical Institutions (5, 13). Normal breast, skin, colon, appendix, and tonsil and the phyllodes tumor were from the Department of Cellular Pathology at the John Radcliffe Hospital (Oxford, UK). The cell lines, xenograft, human tumors and normal tissues had been fixed in 10% buffered formalin, processed, and embedded in paraffin using routine procedures.
Materials
Mouse monoclonal anti-p16 INK4a antibody Ab-7 and monoclonal anti-p14 ARF antibodies 14PO2 and 14P03, as well as polyclonal Ab-1 were obtained from LabVision/NeoMarkers (Fremont, CA). Rabbit polyclonal anti-p14 ARF antibodies Ab-1/PC409 and ZF14 were obtained from Oncogene Research Products (via CN BioSciences, Nottingham, UK) and Zymed Laboratories (South San Francisco, CA), respectively. The Elite ABC detection kit was purchased from Vector Laboratories (Burlingame, CA).
Immunohistochemistry
Five m thick paraffin sections were cut onto coated slides and stored at 4°C until used. The experiments were carried out in a Shandon Sequenza immunostainer. The immunohistochemical assay for detecting p16
INK4a in fixed and paraffin-embedded tissues has been described in detail elsewhere (4, 5, 14) . Briefly, after antigen retrieval in 0.1 M EDTA pH8.0 (20 minutes at 95 to 100°C), the sections were reacted with the antip16 monoclonal antibody at 1 g/mL at 4°C overnight. Some of the p16
INK4a staining data had been included in two earlier studies (5, 12) . For p14
ARF IHC, we initially tested all five antibodies (see Results). We chose to optimize reaction conditions for one of them, i.e., monoclonal antibody 14PO2. After dewaxing and rehydration, the endogenous peroxidase activity was quenched for 20 minutes with 0.3% H 2 0 2 in methanol. The sections then underwent antigen retrieval in 0.01 M citrate buffer pH6.0 at 95 to 100°C for 20 minutes (cell blocks) or 40 minutes (tissues). After blocking with 1% horse serum for 20 minutes, the sections were reacted with primary antibody at 1 g/mL (cell blocks) or 4 g/mL (tissues) at 4°C overnight. The detection reactions for both p16 INK4A and p14 ARF followed the Vectastain Elite ABC protocol as suggested by the manufacturer. Diaminobenzidine (from Vector) with hematoxylin counterstain was used for color development. Negative antibody controls were stained under identical conditions. External positive controls for p14 ARF included normal breast, colon, appendix, and tonsil, a phyllodes tumor, and nude mouse xenografts of lung cancer cell lines H417 and H2009. Several cell lines and tumors with known homozygous INK4a deletions served as external negative controls. A specimen was considered positive for p16 INK4A or p14 ARF if there was nuclear staining above any cytoplastic background; cytoplasmic staining itself was disregarded (5) . If the cells of interest failed to show distinct nuclear reactivity, the specimen was considered negative for the respective protein. In tissue sections, admixed stromal, inflammatory, and normal epithelial cells served as positive internal controls.
RESULTS
Development of an Immunohistochemical Assay for p14 ARF
In preliminary experiments, we tested five antip14 ARF antibodies (three polyclonals and two monoclonals) obtained from three companies. After antigen retrieval in 0.1 M EDTA and primary incubation overnight at 1:400 (polyclonals) or 2 g/mL (monoclonals), all five antibodies produced the expected nuclear staining pattern in positive controls. Because the monoclonal antibodies appeared to be more sensitive, we optimized the reaction conditions for one of them, 14PO2 from NeoMarkers. To validate the IHC assay, we used the positive and negative control specimens detailed in the Methods. Variables tested included primary antibody concentration, different antigen retrieval techniques, and different detection reactions, among others. We found it necessary to employ a longer antigen retrieval time and higher primary antibody concentration for archival tissues, compared with formalinfixed, paraffin-embedded cell buttons. In cells expressing p14 ARF , the staining pattern was predominantly nuclear, sometimes with nucleolar accentuation, usually associated with some cytoplasmic staining (Fig. 1, A and C) . In some tumors and cell lines, there was strong nucleolar staining. In many cell types, the staining intensity was less than for p16 INK4a , but there seemed to be tissue specific variability. p14
ARF levels appeared to be relatively high in the breast (Fig. 1A ), but lower in other tissues. The protein was expressed by nonneoplastic epithelium of the breast, skin, tonsil, colon and appendix. Nuclear staining could also be detected in a subset of lymphocytes, fibroblasts and endothelial cells serving as convenient internal positive controls in tumor sections. No such staining was observed on negative antibody control stains. Cells devoid of p14 ARF , e.g., those with a homozygous INK4a deletion, typically showed nonspecific cytoplasmic reactivity, but no nuclear staining above the background (Fig.  1B) . To demonstrate the general applicability of our p14 ARF assay to archival specimens, we stained 34 cell buttons and 58 carcinomas. To study the relationship between p14
ARF and p16 INK4a expression in neoplastic cells, the same 92 specimens were stained for p16
INK4a as well. As detailed in Tables 1  and 2 , six cell lines were positive, and 18 were negative for both proteins. Of the six p14 For nine cell lines and 20 pancreatic carcinomas, information about ARF abnormalities at the DNA level was available. No nuclear staining was observed in cell lines with homozygous deletions of the INK4a locus (n ϭ 4), promoter methylation of exon 1␤ (n ϭ 2) or an intragenic mutation (n ϭ 2) ( Table 2 ). Colorectal cancer cell line SW837 has no known ARF abnormality and has an unmethylated exon 1␤ promoter (8) , and this cell line expressed p14
ARF . Similarly, all 12 pancreatic adenocarcinomas with INK4a deletions were p14 ARF negative (Table 4) . No data were available on the exon 1␤ methylation status in these cases. One silent and two frameshift mutations were associated with absence of nuclear staining. In contrast, three missense mutants produced positive nuclear immunoreactivity; two of these cases had identical mutations ( 
IHC, immunohistochemistry; Ϫ, No nuclear staining; ϩ, positive nuclear staining.
TABLE 2. Molecular Status of the INK4a (p16/ARF) Locus and Expression of p16
INK4a and p14
ARF Determined by IHC in Nine Human Cancer Cell Lines
Cell Line p16 ARF DNA Protein DNA Protein
IHC, immunohistochemistry; Ϫ, no nuclear staining by IHC; ϩ, positive staining by IHC; HD, homozygous deletion (9); MSNK, methylation status not known; methyl, promoter methylated (8); unmethyl, promoter unmethylated (8). ARF is deregulated in human neoplasia.
We previously showed that IHC is an effective method to demonstrate abrogation of p16 INK4a function in pathologic specimens (4, 5) , and we set out to develop a similar assay for p14 ARF . IHC allows evaluation of protein expression in specific cells and is applicable to most archival tissues. We are aware of only two previous immunohistochemical studies on p14 ARF expression in human cancers (17, 18) . Both of these used rabbit polyclonal antibodies, which are not commercially available, and only one of them was performed on paraffin sections (17) .
Here we demonstrate that p14 ARF expression can be evaluated in formalin-fixed, paraffin-embedded tissues with commercially available reagents. Although we optimized the assay for only one of the five antibodies tested, monoclonal 14PO2 from NeoMarkers, which has been used before in immunofluorescence assays (19) , it is quite possible that comparable results may be obtained with other anti-p14 ARF antibodies. In agreement with earlier studies, the presence of immunoreactive p14 ARF was indicated by granular or diffuse nuclear staining, with or without nucleolar accentuation (17, 18) ; cytoplasmic staining was observed even in cells with homozygous deletions of the INK4a gene and may thus be nonspecific. In some normal cells, cell lines and tumors, the staining pattern was predominantly nucleolar, consistent with the recently described nucleolar sequestration of MDM2 by p14 ARF (7, 19, 20) . The significance of the somewhat variable subcellular localization is unclear, but it does not seem to be related to fixation. INK4a is partly cell cycle dependant (21) . It is conceivable that intracellular p14 ARF levels are subject to similar variability, although we are not aware of detailed published studies on the regulation of p14 ARF expression in normal or neoplastic cells.
The IHC reaction pattern in cell lines and tumors correlated well with the molecularly defined status of the INK4a gene that was available for some cell lines and for many of the pancreatic cancers, and with previous studies on p14 ARF expression in some of the cell lines. All cell lines and tumors with homozygous INK4a deletions were devoid of nuclear reactivity above any cytoplasmic background. Colorectal carcinoma cell lines RKO and DLD-1 reportedly have methylated exon 1␤ promoters (8) , and both of these failed to express the protein, whereas the unmethylated cancer cell line SW837 was p14 ARF positive. Although some ARF mutations led to negative immunoreactivity, missense mutations produced positive nuclear staining (Tables 2 and 4) . Thus, the presence of nuclear staining does not necessarily indicate the presence of normal p14 ARF . Our data are consistent with earlier findings of p14 ARF mRNA and protein expression in MDA-MB-468 breast cancer cells (20) and with absence of exon 1␤ promoter methylation in many colorectal cancer cell lines (8) . T47D breast cancer cells were previously found to be p14 ARF negative by immunofluorescence but positive by RT-PCR, and U20S osteosarcoma cells were reported to be negative but inducible for p14 ARF (19) . Both cell lines showed nuclear staining in our IHC assay, indicating good sensitivity.
However, the limits of the assay's sensitivity have yet to be determined. It is possible that very low but physiologically significant levels of p14 ARF may not be detectable by paraffin section IHC. Other potential problems with the immunohistochemical approach include variability in stain interpretation (our simple dichotomous scoring system should be rather robust) and a relatively poor signal-to-noise ratio due to seemingly low levels of antigen, especially in non-neoplastic tissues (15) , and significant nonspecific background staining. However, as has been the case with p16
INK4a
, the latter problem is likely to be alleviated by the advent of second generation anti-p14 ARF antibodies with improved sensitivity and specificity.
We found loss of p14 ARF expression in 12 of 30 NSCLC, which is comparable with the rate of p14 ARF down-regulation reported in three previous The second edition of Neoplasms with Follicular Differentiation is everything one would expect from Dr. Bernard Ackerman. Beautifully written and illustrated, intellectually challenging, controversial, and encyclopedic in both breadth of coverage and size, the second edition has more than 200 new photographs with increased emphasis on trichoblastoma and "trichoblastic carcinoma." Dr. Ackerman contends the nature and accurate diagnosis of follicular neoplasms has long been obscured by incomprehensible terminology and illogical classification. I heartily agree, and his attempt to shed light on this perplexing topic is most welcome. Dr. Ackerman proposes a new classification of follicular proliferations based on his method of pattern analysis and carefully defined categories of cyst, malformation, hamartomas, hyperplasias, benign neoplasms, and malignant neoplasms. Proliferations are deemed follicular in nature if they show microscopic evidence of differentiation toward elements of the follicle. This contrasts with classifications based on evidence of origin from follicular elements. This method certainly holds great appeal for those of us outside academe's ivory towers with only our trusty microscopes to guide us, but will no doubt rankle those who feel it would be more scientifically honest to define follicular proliferations based on origin from primordial "follicle" cells.
Many of the proliferations discussed are well-accepted entities such as nevus comedonicus (malformation), fibrous papule (hamartoma), and tricholemmoma (hyperplasia). In addition to reviewing historical, clinical, and histopathologic aspects, Dr. Ackerman manages to embellish even these less controversial entities with wisdom gleaned from his own extensive experience. For example, he notes that, in his opinion, perifollicular fibroma is simply a form of fibrous papule; similarly, most tricholemmomas and inverting follicular keratoses are described as forms of verruca vulgares.
More than half of the book is devoted to his concept of trichoblastoma and trichoblastic carcinoma. Dr. Ackerman encompasses trichoepithelioma, desmoplastic trichoepithelioma, adamantoid trichoblastoma, trichoblastic fibroma, and prototypical trichoblastoma as variants of trichoblastoma. Trichoblastic carcinoma represents its malignant counterpart, based on classic Ackerman criteria of malignancy: asymmetry, poor circumscription, etc. In addition, Ackerman considers basal cell carcinoma to be trichoblastic carcinoma.
Neoplasms with Follicular Differentiation will not appeal to everyone. Dr. Ackerman stakes out positions that are diametrically different from many other experts in dermatopathology. Controversial opinions are stated with the certainty of fact, for example: "solar keratoses are squamous cell carcinomas." Nevertheless, I greatly enjoyed this book and would unabashedly recommend it to readers with a particular interest in dermatopathology. Dr. Ackerman presents a novel view of follicular proliferations in a wonderfully lucid, logical fashion, backing up his claims with extensive black and white and color photographs that are uniformly excellent. The text is in his own imitable style with his usual clarity and flourish. However, this is a book perhaps most appropriate for those with a fairly solid background in dermatopathology who will best appreciate and evaluate the differences between Dr. Ackerman's classification and those of others in the field.
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